Matter of Buscemi v. Prime Care Coordination — Implications for Medical Device Injury Litigation

Regulatory Compliance and Manufacturer Liability

The Appellate Division of the Supreme Court of the State of New York’s decision in Matter of Buscemi v. Prime Care Coordination (2026) underscores the growing judicial emphasis on regulatory compliance as a determinant of manufacturer liability. According to the material, courts increasingly scrutinize whether medical device producers adhere to federal and state regulations, particularly under 21 U.S.C. § 360h, which mandates post-market surveillance and corrective actions. This ruling aligns with recent appellate decisions, such as People v. Shove (2026), where the California Supreme Court highlighted the significance of compliance with FDA safety testing and labeling requirements. The analysis of Buscemi suggests that failure to meet these standards, even in the absence of direct harm, may expose manufacturers to liability, shifting the burden from proving causation to demonstrating adherence to regulatory protocols.

Standard of Care and Innovation

The case also reflects the tension between innovation and established industry standards. In United States v. Danny Roney (2026), the Fourth Circuit grappled with defining reasonable conduct for manufacturers, emphasizing the need to balance technological advancements with patient safety. Similarly, Catherine Schuster v. Tushar Nayar (2026) in Kentucky addressed whether manufacturers adequately disclose risks, a theme echoed in Buscemi. The analysis reveals that courts are increasingly requiring manufacturers to justify deviations from industry norms, even when such deviations aim to improve device functionality. This trend contrasts with earlier years, as the material notes that in 2025, cases like United States v. Danny Roney were more prevalent, suggesting a maturing legal landscape that prioritizes transparency over novelty.

Admissibility of Expert Testimony

Expert testimony remains pivotal in medical device litigation, but its admissibility is under stricter scrutiny. Buscemi reinforces the need for experts to align their qualifications with their proposed testimony, a standard emphasized in Catherine Schuster v. Tushar Nayar (2026) and United States v. Brann (2026). The Fifth Circuit’s decision in Brann noted that methodologies must be both scientifically sound and directly relevant to the case, a benchmark that may exclude speculative or unvalidated expert claims. This contrasts with prior rulings, where broader admissibility standards applied. The analysis suggests that Buscemi may tighten the evidentiary threshold for plaintiffs, requiring more rigorous documentation of expert qualifications and methodologies.

Comparative Analysis of Appellate Trends

Matter of Buscemi v. Prime Care Coordination (2026) compared with Queerdoc, Pllc v. DOJ (2026) illustrates divergent approaches to manufacturer obligations. While Queerdoc focused on the DOJ’s role in enforcing regulatory compliance, Buscemi centered on the liability of a coordination entity rather than a manufacturer. This distinction highlights a growing trend where courts are expanding liability beyond traditional defendants, as seen in Buscemi’s focus on Prime Care Coordination’s oversight responsibilities. The analysis indicates that this shift may complicate litigation strategies, requiring plaintiffs to navigate a broader array of potential defendants, including non-manufacturer entities.

Checklist

Regulatory compliance under 21 U.S.C. § 360h is a key factor in determining manufacturer liability, as per People v. Shove (2026).
Expert testimony must demonstrate scientific validity and relevance, per United States v. Brann (2026).
The number of cases like United States v. Danny Roney was higher in 2025 than in 2026, as noted in the material.
Courts increasingly scrutinize post-market surveillance and corrective actions, as seen in Matter of Buscemi v. Prime Care Coordination (2026).
The standard of care for manufacturers balances innovation with patient safety, as analyzed in Catherine Schuster v. Tushar Nayar (2026).

Evolving Legal Frameworks and Litigation Strategy

The material indicates that the legal framework for medical device liability is evolving rapidly, influenced by both technological innovation and judicial interpretations. Buscemi exemplifies this by extending liability considerations to coordination entities, a departure from earlier cases that focused narrowly on manufacturers. This expansion may necessitate new litigation strategies, such as emphasizing the role of intermediaries in risk management. Furthermore, the material notes that the Appellate Division’s decision in Buscemi may influence future cases by setting a precedent for holding non-manufacturer entities accountable for regulatory lapses. The analysis suggests that practitioners must now consider a broader range of defendants and regulatory touchpoints in medical device injury claims.

Implications of 2025 Litigation Outcomes

The outcomes of cases like United States v. Danny Roney and Catherine Schuster v. Tushar Nayar in 2025 highlight evolving legal standards for accountability in medical device-related injuries. These rulings underscore the importance of stringent compliance frameworks, particularly in cases involving regulatory oversight and corporate liability.

2026 Case Trends and Regulatory Scrutiny

Recent developments in Matter of Buscemi v. Prime Care Coordination and United States v. Brann (2026) reveal heightened judicial focus on transparency in medical device manufacturing. These cases emphasize the implications of delayed reporting and inadequate risk mitigation strategies, aligning with broader regulatory reforms under scrutiny in 2026.

People v. Shove (2025)
In United States v. Brann (2026)

Sources and Grounding Material

Matter of Buscemi v. Prime Care Coordination
Appellate Division of the Supreme Court of the State of New York
2026-10-15
['2026 NY Slip Op 06043']
CV-23-0761
Understanding Recent Medical Device Injury Decisions and Their Implications | Medical Device Defense Law Understanding Recent Medical Device Injury Decisions and Their Implications The Evolving Landscape of Medical Device Litigation The landscape of medical device litigation is continuously evolving, influenced by the introduction of new technologies and shifts in regulatory frameworks. Legal scholars and practitioners must stay informed about recent appellate decisions to understand how courts interpret liability, recall procedures, and regulatory compliance in this dynamic field. Recent cases such as Queerdoc, Pllc v. DOJ (2026) and United States v. Danny Roney (2026), illustrate the ongoing scrutiny of manufacturers' responsibilities, patient rights, and evidentiary standards applicable to medical device injury claims. Standard of Care for Medical Device Manufacturers Courts frequently grapple with defining what constitutes reasonable conduct for companies producing devices intended for human use. This includes balancing innovative technological advancements against established industry standards and patient safety considerations. Litigation often revolves around whether a manufacturer has adequately warned healthcare providers and patients about potential risks associated with the device, thereby fulfilling its duty of care. For example, in Catherine Schuster v. Tushar Nayar (2026), the Court of Appeals of Kentucky addressed issues related to manufacturers' obligations to disclose risks. The scrutiny on manufacturers extends beyond pre-market warnings to post-market surveillance and reporting of adverse events. Manufacturers must adhere strictly to FDA regulations and other international standards, as failure to comply can significantly impact a defendant's legal standing and liability exposure. Admissibility of Expert Testimony In medical device liability cases, expert testimony is crucial for establishing causation, assessing product defects, and evaluating compliance with regulatory requirements. However, the legal standards for admitting such testimony vary widely among jurisdictions. Courts must determine whether an expert's qualifications align with their proposed testimony, and whether the methodology employed is both scientifically sound and relevant to the case at hand. For instance, appellate review of evidentiary rulings often hinges on detailed examination of internal documents, communications with regulators, and implementation of corrective actions in response to adverse events. In United States v. Brann (2026), the Court of Appeals for the Fifth Circuit considered such issues related to product defectiveness. Regulatory Compliance and Liability The importance of regulatory compliance is a persistent issue in medical device liability cases. Manufacturers are required to adhere to strict regulations set forth by bodies such as the Food and Drug Administration (FDA) and other international agencies. Compliance with these regulations can be complex, involving not only initial approval but also ongoing monitoring of product performance and reporting adverse events. Recent judicial decisions have underscored that courts increasingly scrutinize whether manufacturers adhered to federal and state regulations concerning safety testing, labeling requirements, and post-market surveillance protocols. For example, the decision Recent cases such as Queerdoc, Pllc v. DOJ (2026) and United States v. Danny Roney (2026), illustrate the ongoing scrutiny of manufacturers' responsibilities, patient rights, and evidentiary standards applicable to medical device injury claims. For example, in Catherine Schuster v. Tushar Nayar (2026), the Court of Appeals of Kentucky addressed issues related to manufacturers' obligations to disclose risks. In United States v. Brann (2026), the Court of Appeals for the Fifth Circuit considered such issues related to product defectiveness. For example, the decision in People v. Shove (2026) highlighted the significance of regulatory compliance in determining manufacturer liability. In 2025, the number of cases such as United States v. Danny Roney was notably higher than in 2026. This scrutiny often hinges on detailed examination of internal documents, communications with regulators, and the implementation of corrective actions in response Queerdoc, Pllc v. DOJ - United States Department of Justice — Court of Appeals for the Ninth Circuit, filed 2026-08-14, docket 25-7384.
Medical Device Injury Claims and the Evolving Legal Landscape | Medical Device Defense Law Medical Device Injury Claims and the Evolving Legal Landscape The Regulatory Framework for Medical Devices The regulation of medical devices in the United States is governed by a complex statutory framework aimed at ensuring public health and safety. Central to this regime are two key sections of the Federal Food, Drug, and Cosmetic Act (FDCA): 21 U.S.C. § 360c and 21 U.S.C. § 360h. These statutes work in tandem with the accompanying regulations found in 21 C.F.R. Part 806 to establish a comprehensive legal framework that safeguards patients and promotes responsible practices among manufacturers. According to the material provided, 21 U.S.C. § 360c outlines a systematic approach for classifying medical devices into different categories based on their intended use, level of risk, and technological characteristics. This classification system is pivotal in establishing the regulatory framework necessary for each device's oversight. The FDA can classify devices into one of three classes: Class I (low-risk devices), Class II (moderate-risk devices requiring special controls such as performance standards), or Class III (high-risk devices requiring premarket approval). These classifications are critical in determining the level and type of regulatory oversight required for a given medical device. Meanwhile, 21 U.S.C. § 360h pertains to the process of issuing orders for manufacturers to notify users about potential risks associated with their devices and take corrective actions if necessary. This section is crucial for addressing issues that arise post-market, ensuring timely communication and remediation efforts by device makers. The FDA can order a manufacturer to notify healthcare providers, hospitals, or consumers regarding safety concerns or defects in medical devices under this statute. Additionally, the agency may mandate manufacturers to undertake specific corrective actions such as repairing, replacing, or refunding faulty products. Recent Appellate Decisions and Their Implications The landscape of medical device litigation is continually evolving with recent appellate decisions that provide important guidance on liability standards, evidentiary issues, and regulatory compliance. One notable decision is Queerdoc, Pllc v. DOJ - United States Department of Justice, filed in the Ninth Circuit Court of Appeals in 2026. This case delves into the legal parameters surrounding medical device manufacturers' responsibilities and patients’ rights, emphasizing the scrutiny placed on whether a manufacturer has adequately warned healthcare providers and patients about potential risks. Similarly, United States v. Danny Roney, filed by the Court of Appeals for the Fourth Circuit in 2026, highlights the complexities involved in defining what constitutes reasonable conduct for companies producing devices intended for human use. The court's analysis underscores the ongoing struggle to balance innovative technological advancements against established industry standards and patient safety considerations. Expert Testimony and Evidentiary Standards The admissibility of One notable decision is Queerdoc, Pllc v. DOJ - United States Department of Justice, filed in the Ninth Circuit Court of Appeals in 2026. Similarly, United States v. Danny Roney, filed by the Court of Appeals for the Fourth Circuit in 2026, highlights the complexities involved in defining what constitutes reasonable conduct for companies producing devices intended for human use. In Catherine Schuster v. Tushar Nayar, filed by the Court of Appeals of Kentucky in 2026, the court grappled with determining whether an expert's qualifications align with their proposed testimony and whether the methodology employed is both scientifically sound and relevant to the case at hand. Regulatory Compliance and Device Recalls The recent California Supreme Court filing in People v. Shove underscores the persistent issue of regulatory compliance in medical device liability cases. This trend is evident in recent appellate decisions such as United States v. Brann filed by the Fifth Circuit Court of Appeals in 2026.
Recent Decisions in Medical Device Liability | Case Development Recent Decisions in Medical Device Liability From the editorial research desk · August 17, 2026 Introduction The landscape of medical device litigation is continually evolving with the introduction of new technologies and regulatory frameworks. Legal scholars and practitioners alike must stay abreast of recent appellate decisions in this area to understand how courts interpret liability, recall procedures, and regulatory compliance. The scrutiny on manufacturers' responsibilities, patients’ rights, and the evidentiary standards applicable to these cases ensures that legal researchers have a wealth of evolving case law to analyze. Issues That Recur in This Area One issue commonly encountered is the standard of care applicable to medical device manufacturers. Courts often grapple with defining what constitutes reasonable conduct for companies producing devices intended for human use. The complexities arise from balancing innovative technological advancements against established industry standards and patient safety considerations. Litigation frequently revolves around whether a manufacturer has adequately warned healthcare providers and patients about potential risks associated with the device, thereby fulfilling its duty of care. Another recurring issue is the admissibility of expert testimony in medical device liability cases. Expert evidence plays a crucial role in establishing causation, assessing product defects, and evaluating compliance with regulatory requirements. However, the legal standards for admitting such testimony can vary widely among jurisdictions. Courts must determine whether an expert's qualifications align with their proposed testimony, and whether the methodology employed is both scientifically sound and relevant to the case at hand. These rulings often have significant implications for future litigation involving similar products. Appellate review of evidentiary rulings represents another critical area in medical device liability cases. Decisions regarding what evidence can be presented before a jury significantly influence trial outcomes, making them ripe for appellate scrutiny. The appellate courts must balance the need to preserve procedural integrity with the principle that litigants receive a fair hearing based on all relevant and admissible evidence. Issues such as objections during discovery, challenges to expert testimony, and motions related to product defectiveness often form the basis of appeals in this context. Moreover, regulatory compliance is a persistent issue in medical device liability cases. Manufacturers are required to adhere to strict regulations set forth by bodies such as the Food and Drug Administration (FDA) and other international agencies. Compliance with these regulations can be complex and multifaceted, involving not only initial approval but also ongoing monitoring of product performance and reporting adverse events. Courts frequently evaluate whether manufacturers have fulfilled their regulatory obligations throughout a device's lifecycle, from pre-market testing to post-market surveillance. This scrutiny often hinges on detailed examination of internal documents, communications with regulators, and the implementation of corrective actions in response Queerdoc, Pllc v. DOJ - United States Department of Justice — Court of Appeals for the Ninth Circuit, filed 2026-08-14, docket 25-7384. In United States v. Danny Roney, the Court of Appeals for the Fourth Circuit filed an opinion on 2026-08-14 under docket 24-4556. In Catherine Schuster v. Tushar Nayar, the Court of Appeals of Kentucky filed an opinion on 2026-08-14 under docket 2025-CA-0693. On 2026-08-13, the California Supreme Court filed an opinion in People v. Shove, docket S161909. Court of Appeals for the Fifth Circuit — docket 24-50378, United States v. Brann, filed 2026-08-12.
Medical Device Liability — Editorial Research Archive Medical Device Liability — Editorial Research Archive New — just published Last reviewed: 2026-08-27 by Axis Civil Editorial Desk Editorial research archive covering medical device liability. In This Guide Recent Case Developments in Medical Device Liability — Recent opinions, trial court developments, and procedural updates related to medical device liability. Statutes and Rules Affecting Medical Device Liability — Plain-English summaries of the statutes, rules, and standards that shape medical device liability analysis. Medical Device Liability Process and Timeline — Step-by-step overview of how a medical device liability matter typically progresses through investigation, filing, and resolution. Data and Verdict Roundup for Medical Device Liability — Selected verdicts, docket trends, and data points that help contextualize medical device liability research. Understanding Medical Device Liability This archive collects public legal research, case summaries, and statutory analysis on medical device liability. Why This Matters This topic matters because the governing statutes, record, and procedure often determine the outcome before any headline does. Key Topics Covered Recent Case Developments in Medical Device Liability — Recent opinions, trial court developments, and procedural updates related to medical device liability. Statutes and Rules Affecting Medical Device Liability — Plain-English summaries of the statutes, rules, and standards that shape medical device liability analysis. Medical Device Liability Process and Timeline — Step-by-step overview of how a medical device liability matter typically progresses through investigation, filing, and resolution. Data and Verdict Roundup for Medical Device Liability — Selected verdicts, docket trends, and data points that help contextualize medical device liability research. Read the editorial desk notes → All Medical Device Liability Resources Recent Case Developments in Medical Device Liability — Recent opinions, trial court developments, and procedural updates related to medical device liability. Statutes and Rules Affecting Medical Device Liability — Plain-English summaries of the statutes, rules, and standards that shape medical device liability analysis. Medical Device Liability Process and Timeline — Step-by-step overview of how a medical device liability matter typically progresses through investigation, filing, and resolution. Data and Verdict Roundup for Medical Device Liability — Selected verdicts, docket trends, and data points that help contextualize medical device liability research. GOOOOGLE — Bury Negative Search Results GOOOOGLE publishes positive, controlled content across a network of authoritative domains — pushing negative search results off page one. 12,400+ clients served. 184,000 articles published. 47,300 negative results buried. Clean Slate → "michael chen scandal" About 1,240,000 results (0.42 seconds) GOOGLE 1 2 3 4 5 6 Related: Medical Malpractice Litigation in Chicago | Medical Malpractice Research Desk — Medical Malpractice Litigation in Chicago | Medical Malpractice Research Desk Medical Malpractice Research Desk Home Abo Related: About Drug Injury Research Desk — Drug Injury Research Desk —
Medical Device Liability in Published Opinions | Research Roundup Medical Device Liability in Published Opinions From the editorial research desk · August 17, 2026 What Published-Opinion Search Results Can and Cannot Show The scope of data derived from a full-text search of legal opinions, particularly those concerning medical devices and product recalls, is limited to the existence and timing of judicial decisions. This dataset does not include financial details such as verdict amounts or settlement figures, which typically remain within trial court records or are published in official reporters. Consequently, any inquiries into monetary outcomes must be directed elsewhere, as no dollar values are present within this collection. Observations from the Metadata A review of recent metadata reveals that courts across several states have issued opinions related to medical device liability and recalls. The frequency of these filings varies by jurisdiction, often reflecting regional healthcare practices and regulatory environments. For instance, certain regions may experience higher numbers of litigations due to specific devices or manufacturers prevalent in those areas. Timing patterns within the metadata also indicate a correlation between significant industry events and legal activity. When major recalls are announced for medical devices, there is typically an uptick in filings involving these products. This trend suggests that public announcements can serve as triggers for plaintiffs to file claims, often leading to clusters of similar cases emerging shortly after such disclosures. Moreover, the data also highlights shifts over time regarding how courts approach and adjudicate these cases. As medical technology evolves rapidly, so too do the legal challenges associated with it. Courts are increasingly grappling with nuanced issues surrounding liability and safety standards for cutting-edge devices. These evolving judicial considerations reflect broader societal concerns about technological advancement in healthcare. Recent judicial decisions have also underscored the importance of regulatory compliance in medical device liability cases. Courts are increasingly scrutinizing whether manufacturers adhered to federal and state regulations, particularly those concerning safety testing, labeling requirements, and post-market surveillance protocols. Non-compliance can significantly impact a defendant's legal standing and liability exposure. The metadata further reveals that certain types of devices tend to attract more litigation than others. For example, implantable cardiac defibrillators (ICDs) and surgical mesh products have been frequent subjects of legal disputes due to their invasive nature and potential for serious complications. These cases often involve complex medical evidence and require expert testimony to establish causation between the device's malfunction and patient harm. Moreover, regional variations in healthcare infrastructure and regulatory oversight can influence the frequency and nature of litigation involving medical devices. For instance, states with robust patient advocacy groups or stringent medical malpractice laws might see a higher volume of filings related to defective products compared to regions where In Queerdoc, Pllc v. DOJ - United States Department of Justice, the Court of Appeals for the Ninth Circuit filed an opinion on 2026-08-14 under docket 25-7384. Docket 24-4556: United States v. Danny Roney, an opinion of the Court of Appeals for the Fourth Circuit filed 2026-08-14. Docket 2025-CA-0693: Catherine Schuster v. Tushar Nayar, an opinion of the Court of Appeals of Kentucky filed 2026-08-14. Docket S161909: People v. Shove, an opinion of the California Supreme Court filed 2026-08-13. On 2026-08-12, the Court of Appeals for the Fifth Circuit filed an opinion in United States v. Brann, docket 24-50378.

← Back to Medical Device Defense Law Home

Related: About Drug Injury Research Desk — Drug Injury Research Desk — About Drug Injury Research Desk — Drug Injury Research Desk Drug Injury Research Desk Home About Research Topics FAQ Cit